Celldex Differentiated Immuno-Oncology Asset Ripe For Combos
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Celldex Therapeutics will initiate Phase I/II trials of its immunotherapy varlilumab in combination with Bristol’s PD-1 inhibitor nivolumab this year and is exploring multiple other combinations.